In this article, we will be taking a look at the 5 Best Biotech Stocks to Buy According to Analysts. If you wish to see the full list, visit 10 Best Biotech Stocks to Buy According to Analysts.

5. Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Price Target Upside: 63.74%

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the best biotech stocks on this list.

TheFly reported on June 10 that UBS increased its price target on CLDX to $45 from $38 while maintaining a Buy rating on the shares. The firm noted that Barzolvolimab’s Phase 3 chronic spontaneous urticaria (CSU) program has a favorable development outlook and could support a potential approval in 2027.

In addition to that, more recently, on June 14, Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented updated long-term findings from its Phase 2 study of barzolvolimab during a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting. The results showed that barzolvolimab provided rapid and sustained improvements in angioedema symptoms among patients with chronic spontaneous urticaria who had not responded adequately to antihistamine treatment. The benefits remained evident seven months after patients completed dosing, highlighting the potential durability of the treatment effect. The findings further support barzolvolimab’s ability to move CSU treatment beyond symptom management toward disease modification and reinforce continued evaluation in ongoing Phase 3 CSU trials.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is a clinical-stage biopharmaceutical company developing antibody therapies for inflammatory and autoimmune diseases, led by barzolvolimab for mast cell–driven conditions.

4. Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Price Target Upside: 69.67%

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the best biotech stocks on this list.

TheFly reported on June 18 that Baird increased its price target on NRIX to $33 from $26 while maintaining an Outperform rating on the shares. The firm adjusted its valuation to account for the company’s partnership with Roche and continued progress across its clinical programs.

Separately, earlier on June 11, Nurix Therapeutics, Inc. (NASDAQ:NRIX) reported updated clinical findings from its ongoing NX-5948-301 Phase 1a/b trial evaluating bexobrutideg (NX-5948), an investigational oral CNS-penetrant BTK degrader, in patients with chronic lymphocytic leukemia (CLL). The data showed continued durable responses in heavily pretreated patients along with encouraging activity in earlier treatment settings. Across 142 Phase 1a/b CLL patients, bexobrutideg demonstrated a favorable safety profile, with no dose-limiting toxicities or treatment-related Grade 5 adverse events. In relapsed/refractory CLL patients, the therapy achieved an objective response rate of 83% with a median progression-free survival of 22.1 months. Earlier-line cohorts also showed strong activity, including ORRs of 92.9% and 84.2% in evaluated groups. The results support further development of bexobrutideg, including a planned Phase 3 monotherapy program.

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies and other treatments for cancer and autoimmune diseases.

3. Jade Biosciences, Inc. (NASDAQ:JBIO)

Price Target Upside: 104.82%

Jade Biosciences, Inc. (NASDAQ:JBIO) is one of the best biotech stocks on this list.

TheFly reported on June 15 that UBS initiated coverage of JBIO with a Buy rating and a $45 price target. The firm highlighted JADE101 as the company’s lead program, viewing it as a potential best-in-class therapy in the $20 billion IgA nephropathy market. UBS noted that JADE101 could reach a peak sales potential of approximately $3 billion to $4 billion. The firm also believes the IgA nephropathy market can support multiple successful treatments rather than being dominated by a single therapy.

In addition to that, earlier on June 1, Jade Biosciences, Inc. (NASDAQ:JBIO) announced positive interim findings from its Phase 1 study of JADE101, an investigational anti-APRIL monoclonal antibody being developed for immunoglobulin A nephropathy (IgAN). The trial evaluated JADE101’s safety, tolerability, pharmacokinetics, and pharmacodynamic effects in 32 healthy volunteers across four dose groups. Results showed approximately 70% reductions in IgA levels sustained through 12 weeks at the 700 mg dose, along with strong APRIL suppression and a favorable safety profile. JADE101 was well tolerated at doses up to 1,400 mg, with no serious adverse events reported. The company advanced JADE101 into Phase 2 development and plans a Phase 3 trial in the first half of 2027.

Jade Biosciences, Inc. (NASDAQ:JBIO) is a clinical-stage biotechnology company developing monoclonal antibody therapies for autoimmune and inflammatory diseases, including treatments targeting APRIL pathways in IgAN.

2. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

Price Target Upside: 139.49%

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best biotech stocks on this list.

TheFly reported on June 14 that at ENDO 2026, CRNX presented Phase 2 data from its TouCAHn study evaluating investigational atumelnant in adults with classic congenital adrenal hyperplasia (CAH). The open-label trial assessed the once-daily oral ACTH receptor antagonist candidate, which is being developed for classic CAH and ACTH-dependent Cushing’s syndrome. Results from Cohort 4 showed that atumelnant enabled glucocorticoid dose reductions while maintaining androgen control. At week 12, participants experienced a 67% average reduction in morning serum androstenedione levels, with 7 of 8 patients reaching physiologic glucocorticoid dosing. The therapy was generally well tolerated, with no treatment-related severe or serious adverse events reported. The findings support continued development of atumelnant in later-stage clinical trials.

On the same day, it was reported that Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) presented updated long-term data from its PALSONIFY (paltusotine) clinical development program in acromegaly at ENDO 2026. Pooled results from the open-label extension studies of PATHFNDR-1 and PATHFNDR-2 showed that once-daily oral PALSONIFY maintained disease control and was well-tolerated after two years of treatment. In PATHFNDR-1, patients previously controlled on injectable SRLs maintained stable IGF-1 levels, symptoms, and tumor volume. PATHFNDR-2 showed reductions in IGF-1 levels among patients with uncontrolled acromegaly, with stable symptoms and tumor measurements. Across the pooled population of 167 patients, no new safety concerns were identified.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a commercial-stage pharmaceutical company developing novel treatments for rare endocrine diseases, including PALSONIFY (paltusotine), an approved therapy for related conditions.

1. Ascentage Pharma Group Internat (NASDAQ:AAPG)

Price Target Upside: 182.19%

Ascentage Pharma Group Internat (NASDAQ:AAPG) is one of the best biotech stocks on this list.

TheFly reported on June 15 that Oppenheimer initiated coverage of AAPG with an Outperform rating and a $45 price target. The firm highlighted the company’s recent clinical presentations, including two oral presentations on olverembatinib at ASCO and early clinical findings from APG-115. Oppenheimer also noted AAPG’s previously reported year-end financial position, with $353 million in cash expected to fund operations through 2027.

On June 14, Ascentage Pharma Group Internat (NASDAQ:AAPG) announced that seventeen clinical updates from its core programs were presented at the European Hematology Association (EHA2026) Congress, including eight poster presentations. The data highlighted ongoing studies of olverembatinib (HQP1351) and lisaftoclax (APG-2575) across multiple hematologic malignancies. Olverembatinib demonstrated sustained clinical activity in chronic myeloid leukemia (CML), including patients with TKI resistance, while updated results from the POLARIS-1 Phase 3 study supported its potential in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Lisaftoclax data from CLL/SLL studies provided additional insights into treatment strategies, with real-world findings also showing clinical utility in myeloid neoplasms. The company continues advancing global development of these therapies and exploring combination treatment approaches.

Ascentage Pharma Group Internat (NASDAQ:AAPG) is a global clinical-stage biotechnology company developing innovative therapies for cancer, chronic hepatitis B, and age-related diseases.

READ NEXT: 10 Best Future Stocks to Buy and Hold for 10 Years and 10 Most Promising Long-Term Stocks to Buy According to Analysts.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.